Patients who received andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding or reversal before surgical procedures N=25; male 10; female 15; age (median, IQR) 75 (71-83); indication for anticoagulation: Afib 15/25, DVT 9/25, peripheral arterial disease 1/25; FXa inhibitor: apixaban 20, rivaroxaban 5. Here, F10 is linked to peripheral arterial disease.